Communiqués SCYNEXIS, Inc.

Actions

SCYX

US8112923094

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/07/2026			Varia. 5j.	Varia. 1 janv.
4,380 ^USD	-4,05%		-1,13%	-13,43%

30/06	SCYNEXIS, Inc. lance une étude de phase 1 sur le SCY-770 pour le traitement de la polykystose rénale autosomique dominante	CI
30/06	Scynexis lance une étude de phase 1 sur le SCY-770 pour le traitement de la polykystose rénale autosomique dominante	MT

Communiqués

30/06	SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	AQ
22/05	SCYNEXIS Announces One-for-Eight Reverse Stock Split	AQ
11/05	Scynexis: Q1 Earnings Snapshot	AQ
11/05	SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
07/05	SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	AQ
31/03	SCYNEXIS Announces $40.0 Million Private Placement	AQ
31/03	SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	AQ
04/03	Scynexis: Q4 Earnings Snapshot	AQ
04/03	SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update	AQ
26/02	SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247	AQ
29/01	SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting	AQ
28/01	SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)	AQ
21/01	SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247	AQ
22/12	SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement	AQ
19/11	SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK	AQ
17/11	Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections	AQ
05/11	Scynexis: Q3 Earnings Snapshot	AQ
05/11	SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
15/10/25	SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study	AQ
30/09/25	SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)	AQ
04/09/25	SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)	AQ
25/08/25	SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025	AQ
13/08/25	Scynexis: Q2 Earnings Snapshot	AQ
13/08/25	SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update	AQ
13/08/25	District Of New Jersey Dismisses Putative Securities Class Action Against Pharmaceutical Company	AQ